Overview

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Status:
Completed

Trial end date:
2005-07-01

Target enrollment:

Participant gender:

Summary

This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole